Irene Casáns-Tormo

Irene Casáns-Tormo

Auto-generated profile, based on publicly available information

Irene Casáns-Tormo

Nuclear Medicine Department, Hospital Clínico Universitario, Valencia, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2022 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
JAJ. C. Alonso
J. C. Alonso
ICI. Casans
I. Casans
FGF. M. González
F. M. González
DFD. Fuster
D. Fuster
ARA. Rodríguez
A. Rodríguez
NCNataly Espinoza Cámac
Nataly Espinoza Cámac
Background: Transarterial radioembolization (TARE) with yttrium-90 microspheres is a clinically effective therapy for hepatocellular carcinoma (HCC) treatment. This study aimed to perform a systematic review of the available economic evaluations of TARE for the treatment of HCC. Methods: The Preferred Reported Items for Systematic reviews and Meta-Analyses guidelines was followed by applying a search strategy across six databases. All studies identified as economic evaluations with TARE for HCC treatment in English or Spanish language were considered. Costs were adjusted using the 2020 US dollars based on purchasing-power-parity ($US PPP). Results: Among 423 records screened, 20 studies (6 cost-analyses, 3 budget-impact-analyses, 2 cost-effectiveness-analyses, 8 cost-utility-analyses, and 1 cost-minimization analysis) met the pre-defined criteria for inclusion. Thirteen studies were published from the European perspective, six from the United States, and one from the Canadian perspectives. The assessed populations included early- (n = 4), and intermediate-advanced-stages patients (n = 15). Included studies were evaluated from a payer perspective (n = 20) and included both payer and social perspective (n = 2). TARE was compared with transarterial chemoembolization (TACE) in nine studies or sorafenib (n = 11). The life-years gained (LYG) differed by comparator: TARE versus TACE (range: 1.3 to 3.1), and TARE versus sorafenib (range: 1.1 to 2.53). Of the 20 studies, TARE was associated with lower treatment costs in ten studies. The cost of TARE treatment varied widely according to Barcelona Clinic Liver Cancer (BCLC) staging system and ranged from 1311 $US PPP/month (BCLC-A) to 71,890 $US PPP/5-years time horizon (BCLC-C). The incremental cost-utility ratio for TARE versus TACE resulted in a 17,397 $US PPP/Quality-adjusted-Life-Years (QALY), and for TARE versus sorafenib ranged from dominant (more effectiveness and lower cost) to 3363 $US PPP/QALY. Conclusions: Economic evaluations of TARE for HCC treatment are heterogeneous. Overall, TARE is a cost-effective short- and long-term therapy for the treatment of intermediate-advanced HCC.

1 November 2021 in Revista Española de Medicina Nuclear e Imagen Molecular
Verified
Journal Article
Closed access
ICI. Casáns-Tormo
I. Casáns-Tormo
JAJ.E. Alcalá-López
J.E. Alcalá-López
CEC. Espinet-Coll
C. Espinet-Coll
VPV. Pubul-Núñez
V. Pubul-Núñez
IMI. Martínez-Rodríguez
I. Martínez-Rodríguez

1 July 2020 in Revista Española de Medicina Nuclear e Imagen Molecular
Verified
Journal Article
Closed access
FMF.J. de Haro-Del Moral
F.J. de Haro-Del Moral
VPV. Pubul-Núñez
V. Pubul-Núñez
ICI. Casáns-Tormo
I. Casáns-Tormo
AJA. Jiménez-Heffernan
A. Jiménez-Heffernan
RRR. Ruano-Pérez
R. Ruano-Pérez

1 March 2015 in Revista Española de Medicina Nuclear e Imagen Molecular
Verified
Journal Article
Closed access
ICI. Casáns-Tormo
I. Casáns-Tormo
SPS. Prado-Wohlwend
S. Prado-Wohlwend
RDR. Díaz-Expósito
R. Díaz-Expósito
NCN. Cassinello-Fernández
N. Cassinello-Fernández
JOJoaquin Ortega-Serrano
Joaquin Ortega-Serrano

1 March 2015 in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Verified
Journal Article
Closed access
ICI. Casáns-Tormo
I. Casáns-Tormo
SPS. Prado-Wohlwend
S. Prado-Wohlwend
RDR. Díaz-Expósito
R. Díaz-Expósito
NCN. Cassinello-Fernández
N. Cassinello-Fernández
JOJ. Ortega-Serrano
J. Ortega-Serrano

10 May 2017 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
PDF file
AJAmelia Jimenez-Heffernan
Amelia Jimenez-Heffernan
SASantiago Aguade-Bruix
Santiago Aguade-Bruix
ICIrene Casans-Tormo
Irene Casans-Tormo